GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF

GENMAB A/S

Financials through fiscal 2025, year ended Dec 31, 2025

$38.50+1.50 (+4.05%)

Close on Oct 19, 2026

GENMAB A/S income statement

Annual QuarterlyTTM

DKK USD

Millions of DKK, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	–	21,526	16,474	14,505	8,417	10,111	5,366	3,025	2,365
Cost of Revenue	–	985	226	–	–	–	–	–	–
Gross Profit	–	20,541	16,248	–	–	–	–	–	–
Research & Development	–	9,748	7,630	5,562	4,181	3,137	2,386	1,431	874
Selling, General & Admin	–	3,790	3,297	2,676	1,283	661	342	–	–
Operating Expenses	–	14,823	11,153	8,238	5,464	3,798	2,728	1,645	1,021
Operating Income	–	6,703	5,321	6,267	2,953	6,313	2,638	1,380	1,344
Interest Expense	–	1,977	1,624	2,511	702	1,558	7.00	11	352
Interest & Investment Income	–	4,438	1,940	3,189	1,667	1,149	228	243	72
Pretax Income	–	9,164	5,637	6,945	3,918	5,904	2,859	1,612	1,064
Income Tax Expense	–	1,320	1,285	1,493	961	1,146	693	140	-40
Net Income incl. Noncontrolling Interests	–	7,844	4,352	5,452	2,957	4,758	2,166	1,472	1,104
EPS (Basic)(per share)	–	122.21	66.64	83.38	45.22	73.00	34.40	24.03	18.14
EPS (Diluted)(per share)	–	121.36	66.02	82.59	44.77	72.21	34.03	23.73	17.77
Shares Outstanding (Basic, Weighted)(shares)	65	66	66	66	66	65	63	61	61
Shares Outstanding (Diluted, Weighted)(shares)	63	65	66	66	66	66	64	62	62
EBITDA	–	–	5,616	6,629	3,201	6,572	2,777	1,468	1,414

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.